| Item Type | Name |
|
Concept
|
Aged, 80 and over
|
|
Academic Article
|
Central nervous system involvement by multiple myeloma: A multi-institutional retrospective study of 172 patients in daily clinical practice.
|
|
Academic Article
|
Clinical predictors of long-term survival in newly diagnosed transplant eligible multiple myeloma - an IMWG Research Project.
|
|
Academic Article
|
Phase 1 trial of ibrutinib and carfilzomib combination therapy for relapsed or relapsed and refractory multiple myeloma.
|
|
Academic Article
|
Daratumumab plus lenalidomide and dexamethasone versus lenalidomide and dexamethasone in relapsed or refractory multiple myeloma: updated analysis of POLLUX.
|
|
Academic Article
|
Results of an early access treatment protocol of daratumumab in United States patients with relapsed or refractory multiple myeloma.
|
|
Academic Article
|
Evolving changes in M-protein and hemoglobin as predictors for progression of smoldering multiple myeloma.
|
|
Academic Article
|
A phase I, open-label study of siltuximab, an anti-IL-6 monoclonal antibody, in patients with B-cell non-Hodgkin lymphoma, multiple myeloma, or Castleman disease.
|
|
Academic Article
|
Metronomic therapy is an effective salvage treatment for heavily pre-treated relapsed/refractory multiple myeloma.
|
|
Academic Article
|
Patterns of central nervous system involvement in relapsed and refractory multiple myeloma.
|
|
Academic Article
|
Bone marrow abnormalities and early bone lesions in multiple myeloma and its precursor disease: a prospective study using functional and morphologic imaging.
|
|
Academic Article
|
Clinical efficacy of daratumumab monotherapy in patients with heavily pretreated relapsed or refractory multiple myeloma.
|
|
Academic Article
|
Daratumumab monotherapy compared with historical control data in heavily pretreated and highly refractory patients with multiple myeloma: An adjusted treatment comparison.
|
|
Academic Article
|
Mortality by a proxy performance status as defined by a claims-based measure for disability status in older patients with newly diagnosed multiple myeloma in the United States.
|
|
Academic Article
|
A phase 1b study of isatuximab plus pomalidomide/dexamethasone in relapsed/refractory multiple myeloma.
|
|
Academic Article
|
INSIGHT MM: a large, global, prospective, non-interventional, real-world study of patients with multiple myeloma.
|
|
Academic Article
|
Daratumumab plus Lenalidomide and Dexamethasone for Untreated Myeloma.
|
|
Academic Article
|
Outcomes of patients with multiple myeloma refractory to CD38-targeted monoclonal antibody therapy.
|
|
Academic Article
|
Pembrolizumab plus pomalidomide and dexamethasone for patients with relapsed or refractory multiple myeloma (KEYNOTE-183): a randomised, open-label, phase 3 trial.
|
|
Academic Article
|
Pembrolizumab plus lenalidomide and dexamethasone for patients with treatment-naive multiple myeloma (KEYNOTE-185): a randomised, open-label, phase 3 trial.
|
|
Academic Article
|
Final analysis of a phase 1/2b study of ibrutinib combined with carfilzomib/dexamethasone in patients with relapsed/refractory multiple myeloma.
|
|
Academic Article
|
Safety and Cost Benefits of the Rapid Daratumumab Infusion Protocol.
|
|
Academic Article
|
Daratumumab-lenalidomide-dexamethasone vs standard-of-care regimens: Efficacy in transplant-ineligible untreated myeloma.
|
|
Academic Article
|
Greater treatment satisfaction in patients receiving daratumumab subcutaneous vs. intravenous for relapsed or refractory multiple myeloma: COLUMBA clinical trial results.
|
|
Academic Article
|
Exposure-Response and Population Pharmacokinetic Analyses of a Novel Subcutaneous Formulation of Daratumumab Administered to Multiple Myeloma Patients.
|
|
Academic Article
|
Frontline treatment patterns and attrition rates by subsequent lines of therapy in patients with newly diagnosed multiple myeloma.
|
|
Academic Article
|
Dynamic follow-up of smoldering multiple myeloma identifies a subset of patients at high risk of progression.
|
|
Academic Article
|
Health-Related Quality of Life in Transplant-Ineligible Patients With Newly Diagnosed Multiple Myeloma: Findings From the Phase III MAIA Trial.
|
|
Academic Article
|
Bortezomib, lenalidomide, and dexamethasone with or without elotuzumab in patients with untreated, high-risk multiple myeloma (SWOG-1211): primary analysis of a randomised, phase 2 trial.
|
|
Academic Article
|
Subcutaneous daratumumab in Asian patients with heavily pretreated multiple myeloma: subgroup analyses of the noninferiority, phase 3 COLUMBA study.
|
|
Academic Article
|
Ixazomib-lenalidomide-dexamethasone in routine clinical practice: effectiveness in relapsed/refractory multiple myeloma.
|
|
Academic Article
|
Final results of a phase 1b study of isatuximab short-duration fixed-volume infusion combination therapy for relapsed/refractory multiple myeloma.
|
|
Academic Article
|
Treatment outcomes of triple class refractory multiple myeloma: a benchmark for new therapies.
|
|
Academic Article
|
Carfilzomib, dexamethasone, and daratumumab versus carfilzomib and dexamethasone for patients with relapsed or refractory multiple myeloma (CANDOR): updated outcomes from a randomised, multicentre, open-label, phase 3 study.
|
|
Academic Article
|
Adjusted Indirect Treatment Comparison of Progression-Free Survival with D-Rd and VRd Based on MAIA and SWOG S0777 Individual Patient-Level Data.
|
|
Academic Article
|
Prognostic impact of corticosteroid and tocilizumab use following chimeric antigen receptor T-cell therapy for multiple myeloma.
|
|
Academic Article
|
Comparison of infectious complications with BCMA-directed therapies in multiple myeloma.
|
|
Academic Article
|
Alliance A061202: ixazomib, pomalidomide, and dexamethasone for patients with lenalidomide-refractory MM in first relapse.
|